Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dyadic International, Inc. - Common Stock (NQ: DYAI )

1.580 -0.040 (-2.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyadic International, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Dyadic International Earnings Perspective: Return On Capital Employed
Dyadic International (NASDAQ:DYAI) brought in sales totaling $313.29 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 145.67%, resulting in a loss of $4.21... 
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
A Preview Of Dyadic International's Earnings
Dyadic International (NASDAQ:DYAI) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that Dyadic... 
Via Benzinga
Why Phibro Shares Are Trading Higher Today?
Phibro Animal Health Corp (NASDAQ: PAHC) and Dyadic International Inc (NASDAQ: DYAI) have entered into an  
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For March 29, 2022
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million. 
Via Benzinga
This Vaccine Stock Is Now On Janssen Pharmaceuticals, J&J, The White House's Radar
Dyadic International shares were up over 6% on January 3rd. Shares are up over 35% in the last month. 
Via Talk Markets
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Genfit (NASDAQ:GN... 
Via Benzinga
63 Biggest Movers From Friday
Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15... 
Via Benzinga
28 Stocks Moving In Friday's Mid-Day Session
Gainers Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor. X4 Pharmaceuticals, Inc... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ: 
Via Benzinga
This Company has its Sights Set of Transforming the Pharmaceutical Industry With its Efficient C1 Vaccine & Drug Manufacturing Technology
Photo by Testalize.me on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Dyadic International Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Dyadic International (NASDAQ:DYAI) reported Q2 sales of $937.09 thousand. Earnings fell to a loss of $3.85 million, resulting in a 16.92% decrease from last... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Hepion Pharmaceuticals (NASDAQ:HEPA 
Via Benzinga
Market Briefing For Thursday, Aug. 26
Underperformance by many stocks, but few that are really in trouble, is reflective of rising complacency, while technicians are frustrated at the lack of breakouts or breakdowns. That's actually fine,... 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Regencell Bioscience (NASDAQ:RGC) stock rose 100.19% to $30.63 during Wednesday's regular session. Regencell Bioscience's stock is trading at a volume of 8... 
Via Benzinga
54 Biggest Movers From Yesterday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 64.84% to $6.33 during Monday's pre-market session. The market value of their outstanding shares is at $144... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock increased by 25.72% to $2.59 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
48 Stocks Moving In Tuesday's Mid-Day Session
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA... 
Via Benzinga
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
Via Talk Markets
Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
- Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies,... 
From Dyadic International, Inc.
Via AccessWire
Topics Regulatory Compliance Supply Chain
Exposures COVID-19 Legal Regulatory
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) shares rose 20.37% to $3.9 during Thursday's pre-market session. The company's market cap stands at $37.8 million.... 
Via Benzinga
66 Biggest Movers From Yesterday
Gainers Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) shares jumped 50.5% to close at $20.74 on Wednesday. The company, last month, priced its IPO at $11 per share. Dyadic... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Dyadic Stock Jumps On Development Pact With Sorrento For Diagnostics & Therapies For Coronaviruses
Dyadic International Inc (NASDAQ: DYAI) and Sorrento Therapeutics Inc (NASDAQ: SRNE) have announced a binding term sheet for a License Agreement to... 
Via Benzinga
Mid-Afternoon Market Update: Dow Surges Over 200 Points; HyreCar Shares Plunge
Toward the end of trading Wednesday, the Dow traded up 0.61% to 35,480.63 while the NASDAQ fell 0.30% to 14,743.90. The S&P also rose, gaining 0.18% to 4,444.91. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Dyadic International (NASDAQ:DYAI) stock increased by 28.96% to $4.63 during Wednesday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.